News | August 03, 2022
Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.
he US FDA has issued six observations pursuant to the completion of the audit.
He was appointed a Board member and the Chairman in 2012.
Strides is the first Indian company to get approval for the product.
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing
Subscribe To Our Newsletter & Stay Updated
